Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$71.8M+27.7%$69.54M+38.2%$65.86M+36.7%$61.75M+29.4%$56.23M+20.6%
$20.27M+8.2%$20.27M+17.8%$20.28M+31.5%$19.83M+48.1%$18.74M+37.8%
$92.07M+22.8%$89.81M+33.0%$86.15M+35.5%$81.58M+33.5%$74.96M+24.5%
-$92.07M-22.8%-$89.81M-33.5%-$86.15M-41.3%-$81.58M-156%-$74.96M-173%
$5M+54.2%$5.95M+211%$6.96M+3,306%$6.45M+1,154%$3.24M+105%
-$87.07M-21.4%-$83.87M-28.3%-$79.19M-29.2%-$75.13M-131%-$71.72M-176%
-$3.54-$3.42
-$89.43M-23.4%-$87.21M-34.5%-$83.6M-42.7%-$79.07M-168%-$72.49M
-$92.07M-22.8%-$89.81M-33.5%-$86.15M-41.3%-$81.58M-156%-$74.96M-173%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Artiva Biotherapeutics, Inc. profitable?
Artiva Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $87.1M over the trailing twelve months, a -79.3% net margin.
What is Artiva Biotherapeutics, Inc.'s earnings per share?
Artiva Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.54.
Where does Artiva Biotherapeutics, Inc.'s income statement data come from?
Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.